Genomma Lab named Herrera interim CEO and Genomma Lab stock costs EUR 0.65

Published on 10/14/2026 at 12:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At Lang & Schwarz, Genomma Lab stock was EUR 0.65 on October 14, 2026. Third-quarter results are due October 21, 2026, and the call follows October 22, 2026.

Leadership transition and quarterly timing

Genomma Lab announced a 12 to 18-month interim CEO mandate on September 17, 2026.
Second-quarter 2026 sales reached MXN 4.397 billion while net income reached MXN 375 million.
Genomma Lab stock was trading at EUR 0.65 at 12:43 p.m. CEST at Lang & Schwarz on October 14, 2026.

Genomma Lab, MX01LA010006, Illustration mit AI erstellt.

Genomma Lab (ISIN MX01LA010006) was trading at EUR 0.65 at Lang & Schwarz on October 14, 2026, at 12:43 p.m. CEST. The company had named founder Rodrigo Herrera Aspra interim chief executive officer effective January 1, 2027, in a release dated September 17, 2026, extending the transition into a new operating phase.

Three dated company developments

On July 23, 2026, Genomma Lab discussed its second-quarter results, with sales of MXN 4.397 billion and net income of MXN 375 million, according to AInvest and MarketScreener.

On September 17, 2026, PR Newswire reported that Herrera would serve as interim CEO for 12 to 18 months, while Juan Marco Sparvieri would lead through the third quarter and support the transition through December 31, 2026.

On October 1, 2026, Yahoo Finance carried the company's announcement that third-quarter 2026 results would be reported on October 21, 2026, after the Mexican Stock Exchange close, with a conference call on October 22, 2026.

What does the transition change?

Herrera's mandate is tied to an operating-model overhaul supported by artificial intelligence agents across marketing, sales, supply and finance. The model is intended to extend across Genomma Lab's portfolio and 18 countries, while the board searches for a permanent successor.

The second-quarter numbers show why execution matters. Sales fell 6 percent year over year to MXN 4.397 billion, but net income rose 5.5 percent to MXN 375 million, while gross margin reached 64.6 percent, according to AInvest. The contrast leaves revenue momentum and cash conversion as key tests for the incoming leadership.

Stock price and company scale

Genomma Lab's market capitalization was MXN 13.0 billion on October 13, 2026, while the quoted 52-week range was MXN 12.22 to MXN 19.48. The shares are listed on the Mexican Stock Exchange under ticker LABB, and the company operates in healthcare through pharmaceutical and personal care products.

Genomma Lab was trading at EUR 0.65 at Lang & Schwarz on October 14, 2026, at 12:43 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Genomma Lab stock.